Ex-GSK CEO, R&D chief An­drew Wit­ty and Mon­cef Slaoui are jump­ing in­to the biotech VC game

Top phar­ma ex­ecs at the mar­quee com­pa­nies don’t re­al­ly re­tire. Some segue quite nat­u­ral­ly in­to ven­ture cap­i­tal, where their con­tacts and heavy­weight in­dus­try rep­u­ta­tions can fa­cil­i­tate the growth of lit­tle biotech com­pa­nies at a time the VC crowd is en­joy­ing a pro­longed and pop­u­lar boom.

This morn­ing two of the biggest names that once dom­i­nat­ed GSK for a decade, the new­ly re­tired CEO An­drew Wit­ty and long­time R&D chief Mon­cef Slaoui, mapped out their plans to jump in­to the biotech ven­ture cap­i­tal game. Sir An­drew has signed on as a part­ner at Durham, NC-based Hat­teras Ven­ture Part­ners, while Slaoui has joined the Eu­ro­pean team at Medicxi.

“An­drew Wit­ty we be­lieve brings the high­est lev­el of un­der­stand­ing about the phar­ma in­dus­try as a whole,” Hat­teras Gen­er­al Part­ner Bob In­gram tells me, count­ing off Wit­ty’s lead­ing roles in the glob­al com­mer­cial as well as R&D side of the busi­ness.

Wit­ty is land­ing in a group where he al­ready feels quite com­fort­able.

He joined the board at Hat­teras port­fo­lio com­pa­ny G1 re­cent­ly, re­turn­ing to a re­gion where GSK has had deep roots. He spoke at an in­vestors meet­ing in 2008 and then again last year, says In­gram, as he was wind­ing up a lengthy stint at the helm of the phar­ma gi­ant. And In­gram says Wit­ty — like­ly the on­ly knight­ed mem­ber of the biotech ven­ture com­mu­ni­ty — is ex­pect­ed to help ad­vise the firm and its biotech com­pa­nies, lend­ing some of his ster­ling Big Phar­ma rep to the or­ga­ni­za­tion as it grows up new com­pa­nies.

Just yes­ter­day Hat­teras, a big play­er in­volv­ing all things out of UNC, par­tic­i­pat­ed in a $27 mil­lion round for Cam­bridge, MA-based Rodin.

Slaoui was the long­time R&D chief at Glax­o­SmithK­line be­fore he moved to chair the big vac­cines side of the busi­ness at GSK ahead of his re­tire­ment last June. As R&D chief, Slaoui cre­at­ed the dis­cov­ery per­for­mance units that were de­signed to spur more biotech-like think­ing as the DPUs com­pet­ed for re­sources. But the DPUs failed to be­come the in­no­va­tion cen­ters that GSK need­ed — with some of Slaoui’s top bets go­ing bad — and new CEO Em­ma Walm­s­ley is fash­ion­ing her own re­or­ga­ni­za­tion to shake things up once again.

Where GSK did find ma­jor new de­vel­op­ment ini­tia­tives was in vac­cines — Shin­grix — and in HIV, where the com­pa­ny re­mains a key play­er.


The Eu­ro­pean VC firm Slaoui joined to­day has some of the best con­tacts in the in­dus­try, and a grow­ing port­fo­lio of biotechs to its cred­it. But it’s a whole dif­fer­ent world from what Slaoui helped cre­ate at GSK, which spends bil­lions of dol­lars every year on drug re­search with big op­er­a­tions in the US and UK. Medicxi’s part­ners have a rep for re­lent­less thrift, mak­ing their R&D dol­lars, eu­ros and pounds stretch as far as pos­si­ble — and then some.

In a state­ment, Slaoui said he was look­ing for­ward to start­ing, “with funds avail­able to in­vest not on­ly in ear­ly stage as­sets but al­so to build­ing in­no­v­a­tive com­pa­nies through clin­i­cal de­vel­op­ment and mar­ket en­try. I am look­ing for­ward to mak­ing an ac­tive con­tri­bu­tion to se­lect­ing and lead­ing in­vest­ments, and to sup­port­ing am­bi­tious en­tre­pre­neurs to de­vel­op med­i­cines that ul­ti­mate­ly make a dif­fer­ence to pa­tients.”

Not long af­ter leav­ing GSK, the en­thu­si­as­tic and out­go­ing Slaoui start­ed join­ing biotech boards, with wel­comes at SutroVax, mR­NA play­er Mod­er­na as well as the pub­lic out­fit In­tel­lia $NT­LA, one of a hand­ful of CRISPR/Ca9 gene edit­ing star­tups dom­i­nat­ing the field. Then, a lit­tle over a month ago, he dropped off the In­tel­lia crew, cit­ing a con­flict but not ex­plain­ing it.

We’ll see soon what he has planned in that field.


Im­ages: An­drew Wit­ty (top) Bloomberg / Mon­cef Slaoui File Pho­to

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis.

Now, it’s rolling that data out, eager to demonstrate what inspired the global biopharma to go long in a neighboring, but new, disease arena for the pipeline. And the most avid students of the numbers will likely be at Bristol Myers Squibb, who will have a multi-year head start on pioneering the TYK2 space with Sotyktu (deucravacitinib) as Takeda makes its lunge for best-in-class status.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Who are the women break­ing bar­ri­ers in drug de­vel­op­ment? Nom­i­nate them for End­points' an­nu­al re­port

Today, we’re opening nominations for our fifth annual Women in Biopharma R&D special report.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. We’re looking for big thinkers, scientists, executives and other enterprising women who are breaking barriers in drug development and inspiring the next generation of leaders.

Francesco Marincola, newly-appointed Sonata Therapeutics CSO

Kite's head of re­search leaves for Flag­ship start­up Sonata

Another leader is departing Kite Pharma, and will to spend the “last part” of his career exploring how cancer evades the immune system.

Kite’s senior VP and global head of cell therapy research Francesco Marincola left the Gilead CAR-T unit last week for Sonata Therapeutics. Flagship last May unveiled the startup, which was pieced together from two fledgling biotechs Inzen and Cygnal Therapeutics. As CSO, Marincola will lead Sonata’s push to reprogram cancer cells to make them more immunogenic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednesday’s advisory committee hearing to discuss Biogen’s ALS drug tofersen, the FDA appeared open to approving the drug, newly released briefing documents show.

Citing the need for flexibility in a devastating disease like ALS, regulators signaled a willingness to consider greenlighting tofersen based on its effect on a certain protein associated with ALS despite a failed pivotal trial. The documents come after regulatory flexibility was part of the same rationale the agency expressed when approving an ALS drug last September from Amylyx Pharmaceuticals, indicating the FDA’s openness to approving new treatments for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FDA warns Proc­ter & Gam­ble over NyQuil la­bel's in­gre­di­ent list­ings

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

Mar­ket­ingRx roundup: What could a US Tik­Tok ban mean for phar­ma? Pfiz­er, Lil­ly lead phar­ma March Mad­ness ad­ver­tis­ers

Just as pharma marketers finally make moves into TikTok, the threat of a US ban on the social media channel is now looming. Already banned on federal employee phones by an initial Congressional act, more bills and maybe bans are on the way. With rare bipartisan agreement, lawmakers have introduced legislation that would give the US president the power to ban TikTok (although not mentioned by name) and other foreign-owned technology platforms that represent a security threat to the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Chat­G­PT with phar­ma da­ta de­buts for med­ical meet­ings, be­gin­ning with AACR

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.